Rip van winkle wakes up: Development of tuberculosis treatment in the 21st century

Clinical Infectious Diseases

Volumn 50, Issue SUPPL. 3, 2010, Pages

  Burman, William J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PNU 100480; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; DRUG EVALUATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HIV INFECTIONS; HUMANS; MICE; TUBERCULOSIS;

EID: 77951782678     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651487     Document Type: Review

References (81)

1. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769-782.
2. East and Central African, British Medical Research Council. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 1986;67:5-15.
3. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-S279.
4. Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 1958; 39:269-274.
5. Medical Research Council. Specific laboratory tests in streptomycin therapy of tuberculosis. Lancet 1948; 2:862-865.
6. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144(4): 745-749.
7. Frieden T, Sterling T, Pablos-Mendez A, Kilburn J, Cauthen G, Dooley S. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-526. (Pubitemid 23053827)
8. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348(2):119-128. (Pubitemid 36056718)
9. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-10021.
10. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368(9547): 1575-1580. (Pubitemid 44780738)
11. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168(4): 443-1147
12. Shieh F, Snyder G, Horsburgh C, Bernardo J, Murphy C, Saukkonen J. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 2006; 174: 717-721. (Pubitemid 44395341)
13. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37(1):101-112. (Pubitemid 36836652)
14. Tuberculosis Trials Consortium. Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons. Lancet 2002; 360:528-534.
15. Chang KC, Leung CC, Yew WW, Chan SL, Tarn CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174(10):1153-1158.
16. Chang KC, Leung CC, Yew WW, Ho SC, Tarn CM. A nested casecontrol study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170(10):1124-1130.
17. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167(4):603-662.
18. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167(11):1472-1477. (Pubitemid 37363354)
19. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore, Int J Tuberc Lung Dis 2002;6(8):699-705. (Pubitemid 34832150)
20. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003;42(9):819-850. (Pubitemid 36995083)
21. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis. Clin Infect Dis 1999;28:419-430.
22. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007. http://www.cdc.gov/TB/TB-HIV- Drugs/default.htm. Accessed 13 April 2008.
23. Self TH, Morris T. Interaction of rifampin and chlorpropamide. Chest 1980;77(6):800-801.
24. Surekha V, Peter JV, Jeyaseelan L, Cherian AM. Drug interaction: rifampicin and glibenclamide. Natl Med J India 1997; 10(1):11-12.
25. Sullivan EA, Kreiswirth BN, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345(8958):1148-1150.
26. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009; 13(1):79-83.
27. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005;56(6):1058-1062.
28. Devasia R, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in M. tuberculosis: The effect of duration and timing of fluoroquinolone exposure. Am J Resp Crit Care Med 2009; 180:365-370.
29. von Gottberg A, Klugman KP, Cohen C, et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008;371(9618):1108-1113.
30. Schaaf HS, Willemse M, Cilliers K, et al. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med 2009; 7:19.
31. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis, Int J Tuberc Lung Dis 2004;8(5):636-647.
32. Burman WJ, Cotton MF, Gibb DM, Walker AS, Vernon AA, Donald PR. Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med 2008;5(8):e176.
33. Burman WJ. The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am J Med Sci 1997;313:355-363.
34. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tubercle 1978;53:5-12. (Pubitemid 9243249)
35. Jindani A, Baer VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939-949. (Pubitemid 10118376)
36. Jindani A, Dore CJ, Mitchison D. The bactericidal and sterilizing activity of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167:1348-1354. (Pubitemid 36609718)
37. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10(6):605-612.
38. Mitchison D. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147:1062-1063. (Pubitemid 23093839)
39. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12(2):128-138. (Pubitemid 351212403)
40. Joloba ML, Johnson JL, Namale A, et al. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000;4(6):528-536. (Pubitemid 30409169)
41. Garton NJ, Waddell SJ, Sherratt AL, et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008; 5(4):e75.
42. Weiner M, Johnson J, Burman W, et al. Evaluation of a new surrogate endpoint for pharmacodynamics of TB drugs. In: Program and abstracts of the International Conference of the American Thoracic Society (San Francisco). 2007.
43. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007;4(11):e292.
44. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348(22):2175-2185. (Pubitemid 36618128)
45. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348(22):2186-2195. (Pubitemid 36618129)
46. Long MW, Snider DEJ, Farer LS. U.S. Public Health Service trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:879-894.
47. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5(Suppl 3):S440-S445.
48. Aquinas M, Allan WG, Horsfall PA, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J 1972; 1(5803):765-771.
49. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47(7):2118-2124. (Pubitemid 36753560)
50. Peloquin C. What is the 'right' dose of rifampin? Int J Tuberc Lung Dis 2003; 7(1):3-5.
51. Kreis B, Pretert S, Birenbaum J, et al. Two three-month treatment regimens for pulmonary tuberculosis. Bull Int Union Against Tuberc 1976;51:71-75.
52. Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51(8): 2994-2996. (Pubitemid 47206244)
53. Tarn CM, Chan SL, Kam KM, et al. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. Int J Tuberc Lung Dis 2000; 4: 262-267.
54. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4(12):e344.
55. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008; 178(9):989-993.
56. Sirgel FA, Fourie PB, Donald PR, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005; 172(1):128-135.
57. Bock NN, Sterling TR, Hamilton CD, et al. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002; 165(11):1526-1530.
58. 58. Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh TD. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 2005;56(6):1169-1171. (Pubitemid 43009844)
59. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373(9670):1183-1189.
60. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174(3):331-338. (Pubitemid 44156613)
61. Dormán SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-280.
62. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307(5707):223-227.
63. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009;53(3):1290-1292.
64. Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008; 52(10):3568-3572.
65. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52(8): 2831-2835.
66. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360(23): 2397-2405.
67. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405(6789):962-966. (Pubitemid 30435054)
68. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3(11):e466.
69. Hurdle JG, Lee RB, Budha NR, et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother 2008;62(5):1037-1045.
70. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52(10):3664-3668.
71. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009; 53:3720-3725.
72. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine, PA-824, on renal function in healthy subjects. Antimicrob Agents Chemother 2009; 53: 3726-3733.
73. Protopopova M, Hanrahan C, Nikonenko B, et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005;56(5): 968-974. (Pubitemid 41631930)
74. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006; 58(2): 332-337. (Pubitemid 44294944)
75. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007;51(4):1563-1565. (Pubitemid 46586854)
76. Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999s 43(5): 1189-1191.
77. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008; 178(11):1180-1185.
78. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56(1):180-185.
79. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 2006; 52(2):92-96. (Pubitemid 43137390)
80. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53(4): 1314-1319.
81. Williams KN, Brickner SJ, Stover CK, et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009; 180:371-376.